Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesenCell for Refractory Chronic Graft-versus-Host Disease
NCT07826676Phase 1Not yet recruiting
- Sponsor
- Pontifícia Universidade Católica do Paraná
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic graft-versus-host disease (cGVHD), sponsored by Pontifícia Universidade Católica do Paraná. Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 30 days. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07826676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826676.